Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Pharmacogenomics ; 18(3): 201-213, 2017 Feb.
Article in English | MEDLINE | ID: mdl-28084903

ABSTRACT

AIM: We conducted a genome-wide association study on angiotensin-converting enzyme inhibitor-induced cough and used our dataset to replicate candidate genes identified in previous studies. PATIENTS & METHODS: A total of 124 patients and 1345 treated controls were genotyped using Illumina arrays. The genome-wide significance level was set to p < 5 × 10-8. RESULTS: We identified nearly genome-wide significant associations in CLASP1, PDE11A, KCNMB2, TGFA, SLC38A6 and MMP16. The strongest association was with rs62151109 in CLASP1 (odds ratio: 3.97; p = 9.44 × 10-8). All top hits except two were located in intronic or noncoding DNA regions. None of the candidate genes were significantly associated in our study. CONCLUSION: Angiotensin-converting enzyme inhibitor-induced cough is potentially associated with genes that are independent of bradykinin pathways.


Subject(s)
Angiotensin-Converting Enzyme Inhibitors/adverse effects , Cough/chemically induced , Cough/genetics , Genetic Variation/genetics , Genome-Wide Association Study/methods , Population Surveillance , Adult , Aged , Aged, 80 and over , Cough/epidemiology , Female , Genetic Association Studies/methods , Humans , Male , Middle Aged , Population Surveillance/methods , Surveys and Questionnaires , Sweden/epidemiology
2.
Proc Natl Acad Sci U S A ; 110(25): 10258-63, 2013 Jun 18.
Article in English | MEDLINE | ID: mdl-23733953

ABSTRACT

The MYC genes are the most frequently activated oncogenes in human tumors and are hence attractive therapeutic targets. MYCN amplification leads to poor clinical outcome in childhood neuroblastoma, yet strategies to modulate the function of MYCN do not exist. Here we show that 10058-F4, a characterized c-MYC/Max inhibitor, also targets the MYCN/Max interaction, leading to cell cycle arrest, apoptosis, and neuronal differentiation in MYCN-amplified neuroblastoma cells and to increased survival of MYCN transgenic mice. We also report the discovery that inhibition of MYC is accompanied by accumulation of intracellular lipid droplets in tumor cells as a direct consequence of mitochondrial dysfunction. This study expands on the current knowledge of how MYC proteins control the metabolic reprogramming of cancer cells, especially highlighting lipid metabolism and the respiratory chain as important pathways involved in neuroblastoma pathogenesis. Together our data support direct MYC inhibition as a promising strategy for the treatment of MYC-driven tumors.


Subject(s)
Apoptosis/drug effects , Lipid Metabolism/drug effects , Neuroblastoma/drug therapy , Proto-Oncogene Proteins c-myc/antagonists & inhibitors , Thiazoles/pharmacology , Animals , Antineoplastic Agents/pharmacology , Cell Differentiation/drug effects , Cell Line, Tumor , Cell Proliferation/drug effects , Disease Models, Animal , Electron Transport/drug effects , Fatty Acids/metabolism , Humans , Mice , Mice, Nude , Mice, Transgenic , Mitochondria/drug effects , Mitochondria/metabolism , Neuroblastoma/metabolism , Neuroblastoma/pathology , Proto-Oncogene Proteins c-myc/metabolism , Receptor, trkA/metabolism , Signal Transduction/drug effects , Xenograft Model Antitumor Assays
3.
Am J Pathol ; 180(2): 494-504, 2012 Feb.
Article in English | MEDLINE | ID: mdl-22115707

ABSTRACT

Small cell lung carcinoma (SCLC) is extremely aggressive and frequently metastasizes widely in its early stage. Because tumor hypoxia is related to aggressive tumor behavior and the hypoxic adaptation of SCLC is poorly documented, we stained SCLC tumors arranged in a tissue microarray for hypoxia-inducible factor (HIF)-1α and HIF-2α proteins. We found an overall lack of HIF-2α protein expression, which was confirmed in large tumor sections. HIF-1α protein was strongly expressed in most tumors, frequently adjacent to necrotic regions. In concordance, cultured SCLC but not non-small cell lung carcinoma cells showed no or extremely low levels of HIF-2α mRNA and no HIF-2α protein at hypoxia. HIF-1α was stabilized after 4 hours at hypoxia, and its accumulation increased up to 96 hours. SCLC cells survived well and showed net proliferation and low cell death in modest (1% oxygen) and severe (0.1% oxygen) hypoxia. HIF-1α repression virtually did not influence cell death or viability despite reduced levels of hypoxia-inducible genes, such as BNIP3 and BNIP3L. At 1% oxygen no increased autophagy (LC3B-II activation) or NF-κB signaling were detected, whereas the unfolded protein response was activated at severe hypoxia. Our data indicate that HIFs are not exclusively required for SCLC cell survival at modest or severe hypoxia and that additional, yet uncharacterized, hypoxia-driven adaptation pathways may become activated.


Subject(s)
Basic Helix-Loop-Helix Transcription Factors/deficiency , Hypoxia-Inducible Factor 1, alpha Subunit/antagonists & inhibitors , Lung Neoplasms/metabolism , Small Cell Lung Carcinoma/metabolism , Basic Helix-Loop-Helix Transcription Factors/genetics , Cell Hypoxia/genetics , Cell Hypoxia/physiology , Cell Survival , Humans , Hypoxia-Inducible Factor 1, alpha Subunit/genetics , Lung Neoplasms/physiopathology , NF-kappa B/metabolism , RNA, Messenger/metabolism , Small Cell Lung Carcinoma/genetics , Small Cell Lung Carcinoma/physiopathology , Tumor Cells, Cultured
4.
Mol Cancer Ther ; 8(1): 160-70, 2009 Jan.
Article in English | MEDLINE | ID: mdl-19139125

ABSTRACT

Small cell lung carcinoma (SCLC) is an extremely aggressive form of cancer and current treatment protocols are insufficient. SCLC have neuroendocrine characteristics and show phenotypical similarities to the childhood tumor neuroblastoma. As multidrug-resistant neuroblastoma cells are highly sensitive to arsenic trioxide (As2O3) in vitro and in vivo, we here studied the cytotoxic effects of As2O3 on SCLC cells. As2O3 induced pronounced cell death in SCLC cells at clinically relevant concentrations, and also at hypoxia. SCLC cells were more sensitive than non-SCLC cells to As2O3. Cell death was mainly due to necrosis, although apoptotic responses were also seen. A significant in vivo effect of As2O3 on SCLC growth was shown in a nude mice-xenograft model, although a fraction of the treated tumor-bearing animals did not respond. The nonresponding SCLC tumors differed in morphology and cell organization compared with treatment-responsive tumors, which in turn, showed decreased vascularization and higher expression of neuroendocrine markers compared with control tumors. Our results suggest a potential clinical application of As2O3 in SCLC therapy. In addition to cell death induction, antiangiogenic induction of differentiation may also be part of the in vivo effect of As2O3 on SCLC growth, as suggested by an increase in neuroendocrine markers in cultured cells.


Subject(s)
Antineoplastic Agents/toxicity , Lung Neoplasms/drug therapy , Lung Neoplasms/pathology , Oxides/toxicity , Small Cell Lung Carcinoma/drug therapy , Small Cell Lung Carcinoma/pathology , Animals , Antineoplastic Agents/therapeutic use , Arsenic Trioxide , Arsenicals/therapeutic use , Biomarkers/metabolism , Caspase 3/metabolism , Cell Death/drug effects , Cell Differentiation/drug effects , Cell Hypoxia/drug effects , Cell Line, Tumor , Enzyme Activation/drug effects , Female , Humans , Lung Neoplasms/metabolism , Mice , Mice, Nude , Oxides/therapeutic use , Small Cell Lung Carcinoma/metabolism , Xenograft Model Antitumor Assays , bcl-2-Associated X Protein/metabolism
5.
Environ Int ; 35(5): 771-4, 2009 Jul.
Article in English | MEDLINE | ID: mdl-19013646

ABSTRACT

Unused prescription drugs can pose a security risk particularly for children or addicts; and they can pose an environmental risk if they are not disposed of properly through correct destruction. The general recommendation in Sweden is to return the unused medicines to a pharmacy. The Swedish Association of the Pharmaceutical Industry AB (LIF) has together with the Swedish retail chain Apoteket AB conducted surveys in 2001, 2004 and 2007 to investigate the level of knowledge in the general public on this issue. The result from the survey in 2007 shows, inter alia: 85% knew that correct disposal was to return unused medicines to a pharmacy and 43% had in fact returned their medicines to a pharmacy during the last 12 months. Of those who saved their medicines, 55% implied they would in the future return it to a pharmacy. 50% answered that they returned the unused medicines for environmental reasons and 42% answered that they worry about the environmental impact of medicines. Comparing the results from the earlier surveys it can be concluded that an increasing number of the Swedish population does return unused medicines to a pharmacy for correct disposal. Environmental concerns are getting more important than security concerns as a reason for returning unused medicines to a pharmacy and a growing fraction is worried about the environmental impact of pharmaceuticals.


Subject(s)
Prescription Drugs , Refuse Disposal , Adolescent , Adult , Health Knowledge, Attitudes, Practice , Humans , Refuse Disposal/methods , Surveys and Questionnaires , Sweden
SELECTION OF CITATIONS
SEARCH DETAIL
...